<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627872</url>
  </required_header>
  <id_info>
    <org_study_id>2006/959-31/1</org_study_id>
    <nct_id>NCT02627872</nct_id>
  </id_info>
  <brief_title>Clinical &amp; Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>COSMIC</acronym>
  <official_title>Clinical &amp; Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Heart Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vinnova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Foundation for Strategic Research (SSF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is an increasing global health problem, which
      primarily increases among the female population. The purpose of this study is to perform
      in-depth clinical and molecular characterizations of early stage COPD patients, as well as
      healthy never-smoker and at-risk smoking control populations to identify molecularly related
      subgroups patients, including gender-related sub-phenotypes of COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is an umbrella diagnosis defined by obstructive
      lung function impairments, and is likely to be caused by a multitude of etiologies including
      environmental exposures, genetic predispositions and developmental factors. Due to the
      heterogeneity of the disease, molecular and mechanistic sub-phenotyping of COPD represents an
      essential step to facilitate the development of relevant diagnostic and treatment options for
      this constantly growing patient group. In the Karolinska COSMIC study, the investigators are
      investigating molecular sub-phenotypes of smoking-induced COPD. A particular focus relates to
      recent epidemiological indications of gender differences in both incidence and severity of
      disease, with post-menopausal women being at greatest risk. The study encompasses profiling
      of mRNA, miRNA, proteomes, metabolomes and lipid mediators of from multiple lung compartments
      (airway epithelium, alveolar macrophages, exosomes, and bronchoalveolar exudates) using a
      range of 'omics platforms, in combination with extensive clinical phenotyping of early stage
      COPD patients, never-smokers, and smokers with normal lung function from both genders. The
      primary objective of the study is to identify molecular sub-phenotypes of patients with COPD,
      specifically by correlating clinical phenotypes multi-molecular 'omics profiling from
      multiple lung compartments of early stage COPD patients compared to healthy and at-risk
      control populations. Secondary goals involve identification of subsets of
      prognostic/diagnostic biomarkers for classification of the defined subgroups, as well as
      relevant pharmaceutical targets.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Measured at baseline and up to 10 year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Emphysema, as shown on chest CT scan</measure>
    <time_frame>Measured at baseline and up to 10 year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Airway wall thickness on chest CT scan</measure>
    <time_frame>Measured at baseline and up to 10 year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>COPD status (COPD participants versus control group participants)</measure>
    <time_frame>Measured at baseline and up to 10 year follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular gender differences</measure>
    <time_frame>Measured at baseline</time_frame>
    <description>Molecular levels investigated: mRNA, miRNA, proteome, metabolome, lipidome</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Emphysema</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Chronic Airways Obstruction</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>COPD patients (GOLD I-II)</arm_group_label>
    <description>Participants with mild-to-moderate COPD (GOLD I-II)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smoker Control Group</arm_group_label>
    <description>Actively smoking participants with normal lung function (do not have COPD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Never-smoker Control Group</arm_group_label>
    <description>Healthy participants that never have smoked</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchoalveolar lavage (BAL) cells, BAL fluid, bronchial biopsies, airway epithelial
      brushings, serum, plasma, and blood cells have been collected.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from all groups are recruited from the general population through
        advertisements.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For smokers, at least 10 pack-years of cigarette smoking

          -  For smokers, at least 10 cigarettes/day the past 6 months before study entry
             Spirometry that meets stage I-II of the Global Initiative for Chronic Obstructive Lung
             Disease (GOLD) stages (postbronchodilator forced expiratory volume in 1 second (FEV1)
             of 50%-100% of predicted level and FEV1/forced vital capacity [FEV1/FVC] less than
             0.7) or normal (postbronchodilator FEV1 greater than 80% of predicted level and forced
             expiratory volume in 1 second/forced vital capacity [FEV1/FVC] greater than 0.7)

        Exclusion Criteria:

          -  Other lung diseases

          -  Atopy (defined as positive specific IgE test)

          -  Asthma

          -  Received antibiotics for a COPD exacerbation in the 3 months prior to study entry

          -  Treatment with oral or inhaled glucocorticoids within past 3 months prior to study
             entry

          -  Significant ischaemic heart disease or arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Institutet/Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <state>Sverige</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Sandberg A, Sköld CM, Grunewald J, Eklund A, Wheelock ÅM. Assessing recent smoking status by measuring exhaled carbon monoxide levels. PLoS One. 2011;6(12):e28864. doi: 10.1371/journal.pone.0028864. Epub 2011 Dec 16.</citation>
    <PMID>22194931</PMID>
  </reference>
  <results_reference>
    <citation>Forsslund H, Mikko M, Karimi R, Grunewald J, Wheelock ÅM, Wahlström J, Sköld CM. Distribution of T-cell subsets in BAL fluid of patients with mild to moderate COPD depends on current smoking status and not airway obstruction. Chest. 2014 Apr;145(4):711-722. doi: 10.1378/chest.13-0873.</citation>
    <PMID>24264182</PMID>
  </results_reference>
  <results_reference>
    <citation>Karimi R, Tornling G, Forsslund H, Mikko M, Wheelock Å, Nyrén S, Sköld CM. Lung density on high resolution computer tomography (HRCT) reflects degree of inflammation in smokers. Respir Res. 2014 Feb 24;15:23. doi: 10.1186/1465-9921-15-23.</citation>
    <PMID>24564813</PMID>
  </results_reference>
  <results_reference>
    <citation>Kohler M, Sandberg A, Kjellqvist S, Thomas A, Karimi R, Nyrén S, Eklund A, Thevis M, Sköld CM, Wheelock ÅM. Gender differences in the bronchoalveolar lavage cell proteome of patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013 Mar;131(3):743-51. doi: 10.1016/j.jaci.2012.09.024. Epub 2012 Nov 10.</citation>
    <PMID>23146379</PMID>
  </results_reference>
  <results_reference>
    <citation>Mikko M, Forsslund H, Cui L, Grunewald J, Wheelock AM, Wahlström J, Sköld CM. Increased intraepithelial (CD103+) CD8+ T cells in the airways of smokers with and without chronic obstructive pulmonary disease. Immunobiology. 2013 Feb;218(2):225-31. doi: 10.1016/j.imbio.2012.04.012. Epub 2012 May 4.</citation>
    <PMID>22652413</PMID>
  </results_reference>
  <results_reference>
    <citation>Balgoma D, Yang M, Sjödin M, Snowden S, Karimi R, Levänen B, Merikallio H, Kaarteenaho R, Palmberg L, Larsson K, Erle DJ, Dahlén SE, Dahlén B, Sköld CM, Wheelock ÅM, Wheelock CE. Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD. Eur Respir J. 2016 Jun;47(6):1645-56. doi: 10.1183/13993003.01080-2015. Epub 2016 Mar 10.</citation>
    <PMID>26965288</PMID>
  </results_reference>
  <results_reference>
    <citation>Forsslund H, Yang M, Mikko M, Karimi R, Nyrén S, Engvall B, Grunewald J, Merikallio H, Kaarteenaho R, Wahlström J, Wheelock ÅM, Sköld CM. Gender differences in the T-cell profiles of the airways in COPD patients associated with clinical phenotypes. Int J Chron Obstruct Pulmon Dis. 2016 Dec 20;12:35-48. doi: 10.2147/COPD.S113625. eCollection 2017.</citation>
    <PMID>28053515</PMID>
  </results_reference>
  <results_reference>
    <citation>Karimi R, Tornling G, Forsslund H, Mikko M, Wheelock ÅM, Nyrén S, Sköld CM. Differences in regional air trapping in current smokers with normal spirometry. Eur Respir J. 2017 Jan 25;49(1). pii: 1600345. doi: 10.1183/13993003.00345-2016. Print 2017 Jan.</citation>
    <PMID>28122862</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Asa Wheelock</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The deidentified clinical phenotype data has been disseminated through peer reviewed publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

